StockData
EVMNNYSEPharmaceutical PreparationsFiscal year ends December 31

Evommune, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$5.27+0.10 (+1.93%)

Close on Oct 19, 2026

Market cap
$190.43M
P/E (TTM)
–
Dividend yield
–

Evommune, Inc. revenue by segment

AnnualQuarterlyTTM

No segment breakdown reported

Evommune does not break out revenue by segment, region or product in the tagged data of its filings for this period type.